SAN

99.62

-0.56%↓

EI

248.8

-7.03%↓

SHL.DE

46.38

-7.09%↓

ARGX

535.8

+0.3%↑

PHIA

22.02

-3.97%↓

SAN

99.62

-0.56%↓

EI

248.8

-7.03%↓

SHL.DE

46.38

-7.09%↓

ARGX

535.8

+0.3%↑

PHIA

22.02

-3.97%↓

SAN

99.62

-0.56%↓

EI

248.8

-7.03%↓

SHL.DE

46.38

-7.09%↓

ARGX

535.8

+0.3%↑

PHIA

22.02

-3.97%↓

SAN

99.62

-0.56%↓

EI

248.8

-7.03%↓

SHL.DE

46.38

-7.09%↓

ARGX

535.8

+0.3%↑

PHIA

22.02

-3.97%↓

SAN

99.62

-0.56%↓

EI

248.8

-7.03%↓

SHL.DE

46.38

-7.09%↓

ARGX

535.8

+0.3%↑

PHIA

22.02

-3.97%↓

Search

Fresenius SE & Co KGaA

Gesloten

SectorGezondheidszorg

39.76 0.86

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

38.91

Max

40.19

Belangrijke statistieken

By Trading Economics

Inkomsten

-55M

264M

Verkoop

264M

5.6B

K/W

Sectorgemiddelde

48.146

63.778

Winstmarge

4.689

Werknemers

176,486

EBITDA

-33M

724M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+14.94% upside

Dividenden

By Dow Jones

Volgende Winsten

7 mei 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

1.4B

22B

Vorige openingsprijs

38.9

Vorige sluitingsprijs

39.76

Nieuwssentiment

By Acuity

35%

65%

122 / 386 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Strong Bearish Evidence

Fresenius SE & Co KGaA Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

26 feb 2025, 13:37 UTC

Marktinformatie

European Stocks on Track for Record Close as Earnings Lift Mood -- Market Talk

5 jun 2024, 12:18 UTC

Marktinformatie

Fresenius Helios Guidance Lift Should Drive Consensus Upgrades -- Market Talk

Peer Vergelijking

Prijswijziging

Fresenius SE & Co KGaA Prognose

Koersdoel

By TipRanks

14.94% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 45.4 EUR  14.94%

Hoogste 48 EUR

Laagste 42 EUR

Gebaseerd op 12 Wall Street-analisten die 12-maands prijsdoelen bieden voor Fresenius SE & Co KGaA - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

12 ratings

11

Buy

1

Hold

0

Sell

Technische score

By Trading Central

39.31 / 40.02Steun & Weerstand

Korte Termijn

Strong Bearish Evidence

Gemiddeld Termijn

Weak Bearish Evidence

Lange Termijn

Bullish Evidence

Sentiment

By Acuity

122 / 386 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Fresenius SE & Co KGaA

Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, dialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of critically and chronically ill patients. This segment offers I.V. generic drugs; biosimilar drugs for autoimmune diseases and oncology; enteral and parenteral nutrition products; medical technologies, as well as disposables, infusions pumps, apheresis machines, cell therapy devices, and other products. The Fresenius Helios segment provides clinical and nursing care facilities. The Fresenius Vamed segment provides services for hospitals and other healthcare facilities. This segment also offers operational management of healthcare facilities and provides services to patients. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.